621 research outputs found
Nonlinear charge injection in organic field-effect transistors
Transport properties of a series of poly(3-hexylthiophene) organic field
effect transistors with Cr, Cu and Au source/drain electrodes were examined
over a broad temperature range. The current-voltage characteristics of the
injecting contacts are extracted from the dependence of conductance on channel
length. With reasonable parameters, a model of hopping injection into a
disordered density of localized states, with emphasis on the primary injection
event, agrees well with the field and the temperature dependence of the data
over a broad range of temperatures and gate voltages.Comment: 7 pages, 7 figures, sub. to J. Appl. Phy
Factors' Employment Absorption, Growth and Income Distribution through Foreign Trade: Pakistan's Case
Despite the recent migration of Pakistan's labour to the
Middle East countries, Pakistan is still characterized as a
labour-abundant and capital-scarce developing country. As such, it is
important that Pakistan's production structure should be such as to
employ greater labour and lesser capital per unit of output in the
different sectors of the economy. To provide pertinent information to
the policy makers in this regard, we here try to estimate how much of
labour and capital are employed and absorbed per unit of output in
Pakistan's internationally traded goods
Controlling charge injection in organic field-effect transistors using self-assembled monolayers
We have studied charge injection across the metal/organic semiconductor
interface in bottom-contact poly(3-hexylthiophene) (P3HT) field-effect
transistors, with Au source and drain electrodes modified by self-assembled
monolayers (SAMs) prior to active polymer deposition. By using the SAM to
engineer the effective Au work function, we markedly affect the charge
injection process. We systematically examine the contact resistivity and
intrinsic channel mobility, and show that chemically increasing the injecting
electrode work function significantly improves hole injection relative to
untreated Au electrodes.Comment: 5 pages, 2 figures. Supplementary information available upon reques
Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: Increasingly successful application to older patients
AbstractNon-Hodgkin lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with widely varying biological, histological, and clinical features. For the BÂ cell NHLs, great progress has been made due to the addition of monoclonal antibodies and, more recently, other novel agents including BÂ cell receptor signaling inhibitors, immunomodulatory agents, and proteasome inhibitors. Autologous hematopoietic cell transplantation (auto-HCT) offers the promise of cure or prolonged remission in some NHL patients. For some patients, however, auto-HCT may never be a viable option, whereas in others, the disease may progress despite auto-HCT. In those settings, allogeneic HCT (allo-HCT) offers the potential for cure. Over the past 10 to 15Â years, considerable progress has been made in the implementation of allo-HCT, such that this approach now is a highly effective therapy for patients up to (and even beyond) age 75Â years. Recent advances in conventional lymphoma therapy, peritransplantation supportive care, patient selection, and donor selection (including the use of alternative hematopoietic cell donors), has allowed broader application of allo-HCT to patients with NHL. As a result, an ever-increasing number of NHL patients over age 60 to 65Â years stand to benefit from allo-HCT. In this review, we present data in support of the use of allo-HCT for patients with diffuse large BÂ cell lymphoma, follicular lymphoma, and mantle cell lymphoma. These histologies account for a large majority of allo-HCTs performed for patients over age 60 in the United States. Where possible, we highlight available data in older patients. This body of literature strongly supports the concept that allo-HCT should be offered to fit patients well beyond age 65 and, accordingly, that this treatment should be covered by their insurance carriers
Allogeneic Versus Autologous Stem Cell Transplantation (SCT) For Follicular Lymphoma (FL). The James Comprehensive Cancer Center Experience
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirine is a cluster of differentiation19-targeting antibody-drug conjugate approved by the US Food and Drug Administration for relapsed DLBCL after 2 lines of systemic therapy based on a trial showing a 48.3% overall response rate. The spectrum of its clinical applications is expanding and is now being tested in other B-cell malignancies
Pure red cell aplasia (PRCA) following ABO-incompatible allogeneic bone marrow transplantation
Recommended from our members
Sex differences in the influence of body mass index on anatomical architecture of brain networks.
Background/objectivesThe brain has a central role in regulating ingestive behavior in obesity. Analogous to addiction behaviors, an imbalance in the processing of rewarding and salient stimuli results in maladaptive eating behaviors that override homeostatic needs. We performed network analysis based on graph theory to examine the association between body mass index (BMI) and network measures of integrity, information flow and global communication (centrality) in reward, salience and sensorimotor regions and to identify sex-related differences in these parameters.Subjects/methodsStructural and diffusion tensor imaging were obtained in a sample of 124 individuals (61 males and 63 females). Graph theory was applied to calculate anatomical network properties (centrality) for regions of the reward, salience and sensorimotor networks. General linear models with linear contrasts were performed to test for BMI and sex-related differences in measures of centrality, while controlling for age.ResultsIn both males and females, individuals with high BMI (obese and overweight) had greater anatomical centrality (greater connectivity) of reward (putamen) and salience (anterior insula) network regions. Sex differences were observed both in individuals with normal and elevated BMI. In individuals with high BMI, females compared to males showed greater centrality in reward (amygdala, hippocampus and nucleus accumbens) and salience (anterior mid-cingulate cortex) regions, while males compared to females had greater centrality in reward (putamen) and sensorimotor (posterior insula) regions.ConclusionsIn individuals with increased BMI, reward, salience and sensorimotor network regions are susceptible to topological restructuring in a sex-related manner. These findings highlight the influence of these regions on integrative processing of food-related stimuli and increased ingestive behavior in obesity, or in the influence of hedonic ingestion on brain topological restructuring. The observed sex differences emphasize the importance of considering sex differences in obesity pathophysiology
Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
AbstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an exceedingly rare disorder categorized under acute myeloid leukemia by the World Health Organization. Phenotypically, malignant cells coexpress CD4+ and CD56+ without coexpressing common lymphoid or myeloid lineage markers. BPDCN frequently expresses CD123, TCL1, BDCA-2, and CD2AP. Restriction of CD2AP expression to plasmacytoid dendritic cells makes it a useful tool to help confirm diagnosis. Clonal complex chromosome aberrations are described in two-thirds of cases. Eighty percent of BPDCN cases present with nonspecific dermatological manifestations, prompting inclusion in the differential diagnosis of atypical skin rashes refractory to standard treatment. Prognosis is poor, with a median survival of less than 18 months. No prospective randomized data exist to define the most optimal frontline chemotherapy. Current practice considers acute myeloid leukemia-like or acute lymphoblastic leukemia–like regimens acceptable for induction treatment. Unfortunately, responses are short-lived, with second remissions difficult to achieve, underscoring the need to consider hematopoietic cell transplantation early in the disease course. Allografting, especially if offered in first remission, can result in long-term remissions. Preclinical data suggest a potential role for immunomodulatory agents in BPCDN. However, further research efforts are needed to better understand BPDCN biology and to establish evidence-based treatment algorithms that might ultimately improve overall prognosis of this disease
- …